Ernest Robert de Paolantonio - 04 Oct 2022 Form 4/A - Amendment Insider Report for Journey Medical Corp (DERM)

Reporting relationship: Officer
Issuer ticker: DERM
Reported as of: 04 Oct 2022
Net transaction value: -$24,324
SEC form: 4/A - Amendment
Accepted by SEC: 01 Mar 2023, 20:46:27 UTC
Original report date: 06 Oct 2022
Prior SEC filing: 25 Jul 2022
Source filing: View source filing
Reporting owner signature: /s/ Ramsey Alloush, attorney-in-fact

Key filing fact

Ernest Robert de Paolantonio filed Form 4/A - Amendment for Journey Medical Corp (DERM) on 01 Mar 2023.

Key facts

This page summarizes Ernest Robert de Paolantonio's Form 4/A - Amendment filing for Journey Medical Corp (DERM).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Mar 2023, 20:46.

Change

Previous filing in this sequence was filed on 25 Jul 2022.
Current net transaction value: -$24,324.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DERM transaction

Common Stock, par value $0.0001 per share

Sale

Transaction value: $24,324
Shares: -10,093
Change %: -3.7%
Price: $2.41
Shares after: 259,907
Date: 04 Oct 2022
Ownership: Direct
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Ernest Robert de Paolantonio is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

In connection with the vesting of 40,000 shares on October 1, 2022, a total of 10,093 of such shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

Footnote F2

Due to a clerical error, the original Form 4 filed on October 6, 2022 reflected an acquisition of 10,029 shares in lieu of a disposition of 10,029 shares. The amount of securities beneficially owned following the reported transaction reported in the previously filed Form 4 is correct.

Footnote F3

Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on October 4, 2022, was $2.38 to $2.43. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price.

Footnote F4

Includes restricted stock units, which vest over various time periods.

SEC remarks

As of the date of the original Form 4 filed on October 6, 2022, the Reporting Person was the Chief Financial Officer of the Issuer. In a Current Report on Form 8-K filed by the Issuer with the Securities and Exchange Commission on January 20, 2023, the Issuer announced that the Reporting Person provided notice of his resignation to the Issuer on January 16, 2023 and, as such, is no longer a Section 16 filer as of the date of this amendment.